drug
(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)
Marketedupdated 4mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 27, 2026
3 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Apr 6, 2033patentUS 10039718*PED
- Feb 15, 2033patentUS 8754065*PED
- Feb 15, 2033patentUS 9296769*PED
- Oct 6, 2032formulationUS 10039718
- Aug 15, 2032compositionUS 8754065
- Aug 15, 2032compositionUS 9296769
- Oct 30, 2030patentUS 8633219*PED4.2y
- Apr 30, 2030formulationUS 86332193.7y
- Mar 3, 2030patentUS 8148374*PED3.5y
- Mar 3, 2030patentUS 9891239*PED3.5y
- Sep 3, 2029compositionUS 81483743.0y
- Sep 3, 2029formulationUS 98912393.0y
- Apr 26, 2027patentUS 7635704*PED245d
- Apr 26, 2027patentUS 8981103*PED245d
- Feb 27, 2027patentUS 7176220*PED187d
- Oct 26, 2026compositionUS 763570463d
- Oct 26, 2026compositionUS 898110363d
- Aug 27, 2026compositionUS 71762203d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that